Hormone Therapy for Prostate Cancer Copiague NY

Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found. The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

Local Companies

Bruce Raymond Gilbert
(516) 487-2700
900 Northern Blvd
Great Neck, NY
Jonathan Telsey
(516) 627-6188
535 Plandome Rd
Manhasset, NY
Albert Sutton
(516) 437-4228
1300 Union Tpke Ste 206
New Hyde Park, NY
Bhushan Khashu
(516) 483-2020
226 Clinton St
Hempstead, NY
William Porter
(631) 427-8530
157 E Main St
Huntington, NY
I Deitz
(212) 722-9777
17 E 96th St
Great Neck, NY
Felix Badillo
(516) 627-6188
535 Plandome Road
Manhasset, NY
Mitchell Buchbinder
(516) 437-4228
1300 Union Tpke # 206
New Hyde Park, NY
Robert Nejat
(516) 741-2255
300 Old Country Rd #211
Mineola, NY
Ferdinand Diblasio
(631) 351-3700
120 New York Ave
Huntington, NY
Data Provided by:
  

Provided By:

TUESDAY, Sept. 22 (HealthDay News) -- Hormone therapy to treat advanced prostate cancer can increase the risk of heart disease, but some types of hormone therapy appear to be safer than others, new research has found.

The study included 30,642 Swedish men with either locally advanced prostate cancer or prostate cancer that had spread (metastatic cancer), who had received hormone therapy as primary treatment for their cancer.

The study findings were scheduled to be presented Tuesday at the European Cancer Organization meeting in Berlin.

In a news release from the European Cancer Organization, the researchers described the types of hormone therapy used: removal of the testicles to eliminate the main source of testosterone production; injections of gonadotropin-releasing hormone agonists to reduce testosterone production by the testicles; and anti-androgen pills that block testosterone from attaching to prostate cells. Most of the patients received one treatment, but 38 percent were given two types of drugs, the study authors noted.

The men were followed for an average of three years and monitored for ischemic heart disease, heart attacks, arrhythmia, and heart failure.

"We found that prostate cancer patients treated with hormone therapy had an elevated risk of developing all of the individual types of heart problems and that they were more likely than normal to die from those causes," study lead author Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London, England, said in the news release.

Specifically, hormone therapy was associated with a 24 percent increased risk of heart attack, a 19 percent increased risk of arrhythmia, a 31 percent increased risk of ischemic heart disease, and a 26 percent increased risk of heart failure, the researchers found. The increased risk of heart disease began a few months after the men began hormone therapy.

The study also found that hormone therapy was associated with a 28 percent increased risk of fatal heart attack, a 21 percent increased risk of dying from heart disease, a 26 percent increased risk of death from heart failure, and a 5 percent increased risk of fatal arrhythmia.

"In a more detailed analysis by type of hormone therapy, the lowest increase in risk for ischemic heart disease, heart attack and heart failure was seen in the group taking anti-androgen therapy, and we saw no increase in risk of death from heart disease in this group. Patients on gonadotropin-releasing hormone agonist therapy had the highest risk of these problems," Van Hemelrijck said.

The findings suggest that physicians should consider heart-related side effects when prescribing hormone therapy for prostate cancer patients and may want to refer patients to a cardiologist before the start of hormone therapy, the researchers stated.

More information

The American Urological Association Foundation has more about hormone therapy for prostate cancer.

SOURCE: European Cancer Organization, news release, Sept. 22, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Hormone Therapy for Lung Cancer Copiague NY
Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.
- Open Prostatectomy Versus Laparoscopic Procedure Copiague NY
- Delayed Prostate Cancer Therapy Copiague NY
- Hormone Therapy Copiague NY
- Exercise for Prostate Cancer Copiague NY
- Diagnosis of Prostate Cancer Copiague NY
- Menopausal Hormone Therapy Copiague NY
- Hormone Therapy for Early Prostate Cancer Copiague NY
- Hormone Therapy for Breast Cancer Copiague NY
- Head and Neck Cancer Treatment Copiague NY